A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis

Mult Scler. 2024 Jan;30(1):63-70. doi: 10.1177/13524585231215268. Epub 2023 Dec 22.

Abstract

Background: Despite increasing evidence that Epstein-Barr virus (EBV) plays a causal role in MS, no treatments have been shown to reduce EBV turnover. We studied the effect of famciclovir on salivary EBV shedding in people with MS (NCT05283551) in a pilot, proof-of-concept study.

Methods: People with MS receiving natalizumab provided weekly saliva samples for 12 weeks before starting famciclovir 500 mg twice daily for 12 weeks. Twelve saliva samples were provided on treatment and 12 following treatment. A real-time qPCR Taqman assay was used to detect EBV DNA in saliva. The proportion of saliva samples containing EBV DNA was compared using the Friedman test.

Results: Of 30 participants (19 F; mean age 41 years; median EDSS 3.5), 29 received famciclovir, and 24 completed the 12-week course. Twenty-one participants provided at least one usable saliva sample in all epochs. Ten of the 21 had shedding in at least one sample pre-drug; 7/21 when taking famciclovir (not significant). No difference in EBV DNA copy number was seen. There were no drug-related serious adverse events.

Conclusion: No significant effect of famciclovir on EBV shedding was seen in this small pilot study. Given the low numbers, a small effect of famciclovir cannot be excluded. Salivary EBV shedding in this natalizumab-treated cohort was lower than in previous studies, which requires replication.

Keywords: Epstein–Barr virus; Multiple sclerosis; anti-viral.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • DNA
  • DNA, Viral / analysis
  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / drug therapy
  • Famciclovir
  • Herpesvirus 4, Human
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Natalizumab
  • Pilot Projects
  • Saliva

Substances

  • Famciclovir
  • Natalizumab
  • DNA
  • DNA, Viral

Associated data

  • ClinicalTrials.gov/NCT05283551